Affimed Therapeutics is a mid-clinical stage biotech company focused on exploring its proprietary NK- and T-cell engaging bi- and tri- specific antibodies, called TandAbs as a novel cancer treatment modality. NK and T-cell engaging specific antibodies are designed to bring NK-cells or T-cells into a closer proximity of cancer cells and trigger a signal cascade leading to the destruction of the latter. The major benefits of bi- and tri- specific antibodies is to circumvent the normal regulatory constraints of the NK- and T-cells and enable these cytotoxic cells to eradicate cancer cells directly. Affimed is the leading developer of NK-cell engaging bi- and tri- specific antibodies. The two initial indications addressed by the company’s lead products, AFM13 and AFM11 are Hodgkin and Non-Hodgkin Lymphoma. The company plans to potentially report AFM13 in Hodgkin’s Lymphoma (HL) Phase IIa results in 1H16, and AFM11 in Non-Hodgkin’s Lymphoma (NHL) and acute lymphoblastic leukemia (ALL) Phase I interim study results in2H16. Additionally, they plan to initiate an AFM13 / CPI combination Phase I study in HL in mid-2016 with data potentially available in late 2016/2017. All indications are of orphan indications and have high unmet medical needs. Should the ALL clinical study be successful, the proprietary TandAB antibody could potentially have treatment utility in several other cancers.